Supriya Lifescience Limited — Financials & Forensics
Sector: Healthcare · NSE: SUPRIYA · BSE: 543434 · ISIN: INE07RO01027
18 Aug 2026
Add SUPRIYA to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹530 Cr | ₹461 Cr | ₹570 Cr | ₹696 Cr | ₹828 Cr |
| EBITDA | ₹214 Cr | ₹129 Cr | ₹173 Cr | ₹261 Cr | ₹294 Cr |
| EBITDA margin | 40.4% | 28.0% | 30.3% | 37.4% | 35.5% |
| Profit after tax | ₹152 Cr | ₹90 Cr | ₹119 Cr | ₹188 Cr | ₹209 Cr |
Deeper analysis
Recent filings by Supriya Lifescience Limited
-
Press Release for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed herewith.
13 Aug 2026 · Financial Results
-
Investor Presentation for Results Earnings Call for Unaudited Financial Results for quarter ended Ju
13 Aug 2026 · Financial Results
-
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201
13 Aug 2026 · Board Meeting
Never miss a filing again
About Supriya Lifescience Limited on Indian Stock Alerts
Indian Stock Alerts tracks Supriya Lifescience Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.